VolitionRx Limited (NYSE American: VNRX) announced that NYSE American LLC accepted the company's compliance plan for continued listing on the exchange on April 22, 2026.

The epigenetics company received a notice on February 6, 2026, stating it was not in compliance with NYSE American continued listing standards. The standards require companies to maintain stockholders' equity of at least $2.0 million if they reported losses in two of their three most recent fiscal years, $4.0 million for losses in three of four recent fiscal years, or $6.0 million for losses in five recent fiscal years.

VolitionRx was required to submit a compliance plan by March 8, 2026, outlining actions to regain compliance by August 6, 2027. The company submitted its plan before the deadline.

NYSE American granted VolitionRx until August 6, 2027, to regain compliance with the listing standards. During this period, the exchange will conduct periodic reviews of the company's progress toward meeting the outlined goals and initiatives.

The company's common stock will continue trading on NYSE American during the compliance period, subject to meeting other listing requirements. If VolitionRx fails to regain compliance by the deadline or does not make sufficient progress, NYSE American may initiate delisting proceedings.

The acceptance letter does not affect VolitionRx's business operations or Securities and Exchange Commission reporting requirements. The company stated it intends to take all reasonable measures to regain compliance during the plan period.

VolitionRx develops blood tests for disease detection and monitoring, including some cancers and diseases associated with NETosis such as sepsis. The company operates research facilities in Belgium, the United States, and London.